Wyeth sees part-time reps offsetting full-time cuts

Share this article:

Wyeth will use inside, part-time sales representatives to complement its full-time sales force, which is being reduced by about 25 percent to 30 percent, the company said.
Adding the part-timers will result in a net sales force reduction of about 15 percent, said Bernard Poussot,
Wyeth executive vice president.
"We think we've found a way to cut the waste, the wasted energies of sales reps calling on doctors [and finding it difficult to] get quality time with physicians," he said.
By trimming its full-time ranks, Wyeth aims to reduce the number of reps targeting the same doctor. Sales personnel will be assigned to detail multiple products.
As for part-timers, Wyeth has deployed them in its consumer division for the past few years. As reported in MM&M, the drug maker began piloting them in its pharmaceuticals division in July and said it will fully implement them by year's end (MM&M, July 2005).

 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...